Clarivate PLC Announces $500M Share Repurchase Program

Clarivate PLC (NYSE:CLVT) has announced a new share repurchase program of up to $500 million for the period of January 1, 2025, through December 31, 2026. This new program replaces the current one, under which the company repurchased $300 million of ordinary shares, including $200 million during the third and fourth quarters of 2024. The company also prepaid $75 million of term-loan debt during the fourth quarter, bringing total prepayments in 2024 to $133 million.

Matti Shem Tov, CEO of Clarivate, stated, "As we execute against our value creation plan, we expect to deploy capital to the most value-enhancing opportunities." This new share repurchase program reflects the board's confidence in the company's ability to drive growth and enhanced financial performance.

It's important to note that the new share repurchase program does not obligate Clarivate to repurchase any set dollar amount or number of shares and may be modified, suspended, or terminated at any time without prior notice. Under the new share repurchase program, Clarivate is authorized to conduct open-market purchases of its ordinary shares from time to time through any method or program, subject to availability of ordinary shares, price, market conditions, alternative uses of capital, and applicable regulatory requirements, at management’s discretion. As a result of these announcements, the company's shares have moved -0.5% on the market, and are now trading at a price of $5.45. For the full picture, make sure to review Clarivate's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS